Main Line biopharm CEO stepping down
A Main Line biopharmaceutical company is searching for a new chief executive officer.
Marinus Pharmaceuticals of Radnor said Tuesday its CEO, Christopher Cashman, is leaving the company effective March 18 to pursue other opportunities.
Founded in 2003, Marinus (NASDAQ: MRNS) is focused on developing new medicines to treat to epilepsy and other neuropsychiatric disorders. Its lead new drug candidate, ganaxolone, is being tested as a potential treatment for postpartum depression and acute epilepsy.
In…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: John George Source Type: news